Erasca (ERAS) Current Assets (2020 - 2026)
Erasca posted quarterly Current Assets of $253.8 million for Q1 2026, down 19.34% year-on-year from $314.6 million in Q1 2025, and down 11.34% on a QoQ basis from $286.2 million in Q4 2025.
Erasca (ERAS) has 7 years of Current Assets data on file, last reported at $253.8 million in Q1 2026.
- For the quarter ending Q1 2026, Current Assets fell 19.34% year-over-year to $253.8 million; the trailing twelve-month figure through Mar 2026 stood at $253.8 million (down 19.34% YoY), and the FY2025 full-year result was $286.2 million, down 7.3% from the prior year.
- Current Assets for Q1 2026 stood at $253.8 million, down from $286.2 million in the prior quarter.
- Across five years, Current Assets topped out at $444.5 million in Q4 2022 and bottomed at $253.8 million in Q1 2026.
- The 5-year median for Current Assets is $320.7 million (2023), against an average of $339.5 million.
- The widest annual swing landed in 2022, when Current Assets soared 93.33%; it then decreased 27.86% in 2023.
- A 5-year view of Current Assets shows it stood at $444.5 million in 2022, then fell by 27.86% to $320.7 million in 2023, then declined by 3.71% to $308.8 million in 2024, then decreased by 7.3% to $286.2 million in 2025, then retreated by 11.34% to $253.8 million in 2026.
- The last three Current Assets figures came in at $253.8 million (Q1 2026), $286.2 million (Q4 2025), and $299.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 253.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 253.78 Mn |
| Dec 31, 2025 | 286.24 Mn |
| Sep 30, 2025 | 299.93 Mn |
| Jun 30, 2025 | 310.66 Mn |
| Mar 31, 2025 | 314.62 Mn |
| Dec 31, 2024 | 308.79 Mn |
| Sep 30, 2024 | 330.17 Mn |
| Jun 30, 2024 | 418.01 Mn |
| Mar 31, 2024 | 306.62 Mn |
| Dec 31, 2023 | 320.68 Mn |
| Sep 30, 2023 | 305.97 Mn |
| Jun 30, 2023 | 323.85 Mn |
| Mar 31, 2023 | 397.88 Mn |
| Dec 31, 2022 | 444.50 Mn |
| Sep 30, 2022 | 365.75 Mn |
| Jun 30, 2022 | 381.42 Mn |
| Mar 31, 2022 | 403.37 Mn |
| Dec 31, 2021 | 420.02 Mn |
| Sep 30, 2021 | 492.31 Mn |
| Jun 30, 2021 | 197.29 Mn |
| Dec 31, 2020 | 119.99 Mn |